Bibliography
- SOKOLOFF P, GIROS B, MARTRES MP, BOUTHENET ML, JC: Molecular cloning and characterisation of a novel dopamine receptor D3 as a target for neuroleptics. Nature (1990) 347:146–151.
- ••The cloning of the D3 dopamine receptor.
- SIBLEY DR, MOUSMA FJ: Molecular biology ofdopamine receptors. Trends Pharmacol. Sci. (1992) 13:61–69.
- SEEMAN P, VAN TOL HM: Dopamine receptor pharma-cology. Trends Pharmacol. Sci. (1994) 15:264–270.
- SCHWARTZ JC, CARLSON A, CARON M et al: Dopaminereceptors. In: The IUPHAR Compendium of Receptor Characterization and Classification. IUPHAR (Ed.) Media 68, London, UK, (1998):142–151.
- •State of the art paper for the dopamine receptors, all the receptors DI - D5 are reported with the sequences and the ligands.
- LEVESQUE D, DIAZ J, PILON C et al.: Identification, and localisation of the D3 receptor in rat brain using 743111-hydroxy-N,N-di-n-propy1-2-aminotetralin. Proc. Nod Acad. Sci. USA (1992) 89:8155–8159.
- CAINE SB, KOOG GF: Modulation of cocaine-administration in the rat through D3 dopamine receptors. Science (1993) 260: 1814-1816
- ••Important for the putative use of D3 ligands in respect to theD2 receptor, for example in drug addiction.
- SAUTEL F, GRIFFON N, SOKOLOFF P et al.: Nafadotride, a potent preferential dopamine D3 receptors antagonist activates locomotion in rodents. J. Pharm. Exp. Ther. (1995) 275:1239–1247.
- AUSTIN NE, AVENELL KY, BOYFIELD I et al: Novel 1,2,3,4-tetrahydroisoquinolines with high affinity and selectivity for the dopamine D3 receptor. Bioorg. Med. Chem. (1999) 9:179–184.
- MURAY PJ, HELDEN RM, JOHSON MR et al: A novel series of arylpiperazines with high affinity and selectivity for the dopamine D3 receptor. Bioorg. Med. Chem. (1996) 4:403–408.